Cannabis (Marijuana): Dependence, Withdrawal, and Recovery Support

Cannabis is the most widely used drug in the country after alcohol and nicotine, and the one people most often tell us they "can't really be addicted to." The numbers say otherwise: 61.6 million Americans aged 12 or older used it in the past year (SAMHSA NSDUH, 2025), and the CDC estimates that "approximately 3 in 10 people who use cannabis have cannabis use disorder" (CDC, 2024). Stopping is rarely medically dangerous, but the sleep loss and flat mood of the first two weeks send a lot of people back before the brain has a chance to reset. This page covers what THC does, how use disorder and withdrawal are defined, how treatment and testing work, and how weekly support at home fits.

What cannabis is and how it works

The DEA describes marijuana as "a mind-altering (psychoactive) drug, produced by the Cannabis sativa plant," with THC (delta-9-tetrahydrocannabinol) as "the main ingredient that produces the psychoactive effect" (DEA, 2025). CBD, the other cannabinoid people know, by itself "is not impairing, meaning it does not cause a 'high'" (CDC, 2024). Flower goes by weed, pot, bud, herb, ganja, chronic, and dozens of other names (DEA); concentrates are wax, shatter, budder, dabs, butane hash oil (BHO), 710, and the vape cartridges most young adults now use (DEA, 2020).

THC acts on cannabinoid receptors in the brain, the system that regulates appetite, mood, memory, and sleep. THC is fat-soluble: the FDA label for dronabinol, which is "synthetic delta-9-tetrahydrocannabinol," reports a large volume of distribution "because of its lipid solubility" and a terminal half-life of "25 to 36 hours" (Marinol prescribing information, 2026). It soaks into body fat and leaks back out for days, which is why urine tests stay positive for weeks. And edibles are slow: they "can take up to 2 hours to feel the effects," which is how people take a second dose before the first lands (CDC FAQ, 2025).

Potency is what has changed most. The CDC reports that in seized cannabis "the average delta-9 THC concentration almost doubled, from 9% in 2008 to 17% in 2017," and that in dispensary products "the average THC concentration was 22%, with a range of 0% to 45%" (CDC). The clinical summary on NCBI Bookshelf describes dabbing "concentrated extracts (60%-80% THC)" as producing "higher peaks and greater reinforcing potential" (StatPearls, 2026).

Risky use, dependence, and cannabis use disorder are not the same thing

Most people who use cannabis will not develop a problem with it. Some will, and they are not weaker than the ones who don't. Physical dependence is the body adapting to a steady supply of THC; the DEA notes that "Long term, regular use can lead to physical dependence and withdrawal following discontinuation" (DEA, 2025).

Cannabis use disorder is a specific DSM-5 diagnosis, which the CDC describes as being "unable to stop using cannabis even though it's causing health and social problems in their lives" (CDC). The signs are the DSM-5 list in plain language: using more than intended, failing to quit, craving, continuing despite problems at home, school, or work, needing more for the same effect, and withdrawal when stopping (CDC FAQ). In 2025, 6.7 percent of Americans aged 12 or older met criteria in the past year; among young adults aged 18 to 25 it was 14.1 percent (SAMHSA NSDUH, 2025).

The "you can't get addicted to weed" belief rests on a real observation: no one dies from cannabis withdrawal. What it misses is that a use disorder is defined by loss of control and consequences, not by how bad withdrawal is. When a parent says "it's just weed," we ask a different question: what has it started to cost, and can he stop when he decides to?

Signs cannabis has become a problem

What families and members describe to us sounds like this. The first hit now happens before work. A cartridge that used to last two weeks lasts four days. There is real irritability, sometimes anger, when a session gets delayed. Sleep without it has become impossible, and that has quietly become the reason to keep going. School or work has slipped. There have been bouts of relentless vomiting that only a hot shower relieves. Anxiety or paranoia shows up during use now, when it used to be relaxing. Several failed attempts to cut back sit in the background. Driving high is routine; the CDC notes that "after alcohol, cannabis is the substance most often associated with impaired driving" (CDC, 2024). Any one of these is worth a conversation. Several together are worth a call.

Is stopping cannabis dangerous?

Medically, almost never. That is different from alcohol and benzodiazepines, where the FDA warns that stopping abruptly "can result in withdrawal reactions, including seizures, which can be life-threatening" (FDA, 2020). Cannabis withdrawal produces none of that; the clinical summary on NCBI Bookshelf lists uncomplicated withdrawal as an outpatient condition where "Supportive care is the primary therapy" (StatPearls, 2026).

What you may need is a plan for sleep and mood, because those are what break people. Two situations call for a clinician. If cannabis has been covering a depression, anxiety disorder, or PTSD, those come back uncovered, and the CDC notes that cannabis use is "associated with depression; social anxiety; and thoughts of suicide, suicide attempts, and suicide" (CDC, 2024). Anyone with suicidal thoughts during withdrawal should be seen. And if a psychotic episode has ever happened during use, a psychiatrist belongs in the plan from the start.

One more reason to stop is a syndrome many heavy users have never heard of. Cannabis hyperemesis syndrome is "attributed to prolonged, frequent cannabis use, characterized by sudden episodes of severe nausea, vomiting, and abdominal pain." From January 2023 through May 2026 there were 199,565 emergency department visits involving it, with outcomes ranging "from symptom resolution after cessation of cannabis use to, in rare cases, death" (CDC MMWR, 2026). The only lasting fix: "definitive treatment requires sustained abstinence" (StatPearls).

Cannabis withdrawal timeline

Cannabis withdrawal became an official DSM-5 diagnosis in 2013. The criteria require three or more of the following after stopping heavy use: "Irritability, anger, or aggression," "Nervousness or anxiety," "Sleep difficulty (insomnia, disturbing dreams)," "Decreased appetite or weight loss," "Restlessness," "Depressed mood," and at least one physical symptom such as "abdominal pain, shakiness/tremors, sweating, fever, chills, or headache" (SAMHSA, DSM-5 criteria table, 2016). Timing depends on how much, how potent, and how long, and everyone differs. This is the general shape.

First 24 to 72 hours

Because THC stays in body fat, the first day is often easier than expected. Then irritability arrives, with restlessness and a short fuse that surprises the people around you. Appetite drops, and the first night without it is usually the first bad night. Onset is typically "24 hours or less" (StatPearls).

Days 2 to 7

Symptoms peak around "days 2 to 3" (StatPearls). Anxiety, sweating, stomach discomfort, headache, and low mood are common. Sleep is the headline: trouble falling asleep, waking through the night, and vivid dreams that nightly users have not had in years. This is the week most quit attempts end, usually at bedtime.

Weeks 2 to 3

Irritability, appetite, and physical symptoms ease for most people. The syndrome "resolves in approximately 1 to 2 weeks" (StatPearls), but sleep and mood lag, and cravings attach to routines: the drive home, the end of a shift.

Weeks 4 and beyond

Sleep takes longer to settle than the rest, and strange dreams can persist for weeks. Boredom and "what do I even do at night now" are the real work of this stretch. If low mood is still heavy at week six, see a clinician; it may have been there before the cannabis.

How treatment works

There is no medication for this. The clinical summary states that "as of 2025, no pharmacologic therapy is FDA-approved for CUD," and that medication trials "have shown inconsistent or modest benefit" (StatPearls, 2026). Treating an underlying depression or ADHD often does more for cannabis use than anything aimed at the cannabis itself.

What works is behavioral. The same source names "cognitive behavioral therapy (CBT), motivational enhancement therapy, and contingency management" as first-line treatments (StatPearls). CBT teaches you what to do with the trigger instead of the drug; motivational enhancement is the structured version of the "do I even want to quit" conversation. Contingency management is the one families have rarely heard of: SAMHSA defines it as "tangible reinforcers, or motivational incentives" given "contingent on objective evidence of change in a specific, incentivized behavior," lists cannabis use disorder among the conditions it treats, and notes benefit lasting "a median of 24 weeks after reinforcement ended" (SAMHSA, 2025). The "objective evidence" in that definition is a drug test, which is part of why testing sits at the center of what we do.

Sleep deserves its own line in the plan. Most members tell us cannabis became a sleep aid long before it became anything else, and the return of insomnia is the most common reason for a return to use.

Cannabis with alcohol, benzodiazepines, or other drugs

Cannabis on its own does not stop your breathing; the DEA notes that "No deaths from overdose of marijuana have been reported" (DEA, 2025). The risk sits in combinations and impairment. The CDC states that "using alcohol and cannabis at the same time is likely to result in greater impairment than when using either one alone" (CDC FAQ, 2025), and the THC label warns of "additive central nervous system depression" with "alcohol or other CNS depressants such as benzodiazepines and barbiturates" (Marinol prescribing information).

High-potency products are where psychosis risk lives. The Surgeon General's advisory says the risk of psychotic disorders rises "with frequency of use, potency of the marijuana product, and as the age at first use decreases" (HHS, 2019), and the National Academies found "substantial evidence" linking cannabis to "schizophrenia or other psychoses, with the highest risk among the most frequent users" (NASEM, 2017). For teenagers the stakes are higher: the brain "continues to develop until around age 25," and the risk of use disorder "is stronger in people who start using cannabis during youth or adolescence" (CDC, 2024).

Drug testing for cannabis

Cannabis is on every standard panel. Urine tests look for the metabolite THC-COOH, which "is detectable for approximately 3 days after a single use and up to 30 days in chronic users" (StatPearls, 2026). A daily heavy user can stay positive for weeks after a genuine last use, a common source of arguments in the first month. A urine positive at week three does not by itself mean someone used at week three.

Saliva is a shorter window, and it measures the drug itself rather than the metabolite. SAMHSA's testing guide puts oral fluid detection at "the previous 24-48 hours" for drugs in general (SAMHSA TAP 32, 2012), and the federal oral fluid guidelines set a 2 ng/mL confirmation cutoff for THC and cite research in which THC stayed above it "for 32 hours with the occasional users and 72 hours with the frequent users" (Federal Register, 2019). That shorter window is a feature for recovery: a saliva result tells you about the last couple of days, not about a month ago.

Two caveats. CBD products first: the Department of Transportation warns that they "could contain higher levels of THC than what the product label states" and that "CBD use is not a legitimate medical explanation for a laboratory-confirmed marijuana positive result" (DOT, 2020). Second, hemp-derived delta-8 "has psychoactive and intoxicating effects, similar to delta-9 THC" (FDA, 2022), and it will read as THC on a test.

Our members use saliva-based screening that is assigned at random through the week. You do not choose whether you test; you choose who sees the results. For someone stopping cannabis that usually means a spouse or parent, sometimes a therapist or a court. We explain the details in our guide to how sobriety monitoring works.

How recovery from cannabis works with Accountable

We are not a detox and we do not prescribe, and with cannabis you rarely need either. What most people need is structure and a witness through the first ninety days, plus someone who has done it. That is what we provide.

1. Get the full picture

In the first sessions your coach maps what is actually going on: flower or concentrates, how many times a day, how long since a full day without it, whether sleep is the real reason you keep going, and whether alcohol or any history of panic or paranoia is in the picture. If cannabis has been covering for depression, anxiety, or ADHD, we help you find a prescriber or therapist, and with your permission we coordinate so everyone works from the same plan.

2. Build a plan that fits your life

Cannabis is woven into routines in a way other drugs often are not: the wake-and-bake, the drive home, the wind-down. Your coach helps you plan around the real calendar: what replaces the 10 p.m. session, what you will do at 3 a.m. when you are awake and furious about it, who you will text before you open the delivery app. Daily peer group meetings give you people to talk to at the hour you used to smoke, and the weekly family Zoom group gives the people around you their own support.

3. Weekly check-ins through the long stretch

The dangerous window for cannabis is week four, when sleep is better and "one hit to celebrate" sounds reasonable. Your coach shows up every week, and the random saliva screening turns "I think she's stopped" into a shared record that you control. When a return to use happens, we treat it as information: the plan changes and the support goes up. Every coach at Accountable has their own recovery behind them, and some will tell you cannabis was the one they were told did not count.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

Is cannabis actually addictive?

Yes. Cannabis use disorder is a DSM-5 diagnosis, and the CDC estimates that "approximately 3 in 10 people who use cannabis have cannabis use disorder," with higher risk for people who start young or use daily (CDC, 2024).

How long does cannabis withdrawal last?

Symptoms usually begin within a day, peak around days two to three, and ease over one to two weeks (StatPearls, 2026). Sleep problems and vivid dreams often outlast the rest by a few weeks.

How long does cannabis stay in your system?

Urine tests for the THC-COOH metabolite can stay positive for about three days after a single use and up to 30 days in daily heavy users (StatPearls). Saliva tests detect the drug itself for roughly one to three days: federal guidelines cite 32 hours in occasional users and 72 hours in frequent users (Federal Register, 2019).

Can you overdose on cannabis?

Not fatally on its own; the DEA reports no deaths from marijuana overdose (DEA, 2025). Too much, especially edibles or concentrates, can cause panic, a racing heart, vomiting, and hallucinations; the CDC says to call Poison Control at 1-800-222-1222 or 911 (CDC FAQ, 2025). A child who has eaten an edible needs emergency care.

Is there a medication to help quit cannabis?

No. There is no FDA-approved medication for cannabis use disorder (StatPearls, 2026). Treatment is behavioral: CBT, motivational enhancement therapy, and contingency management, which SAMHSA lists as effective for cannabis use disorder (SAMHSA, 2025). A doctor can treat sleep, anxiety, or depression alongside it.

Sources

• Drug Enforcement Administration. Marijuana/Cannabis drug fact sheet, January 2025.

• Drug Enforcement Administration. Marijuana, drug fact sheet web page.

• Drug Enforcement Administration. Drug Fact Sheet: Vaping and Marijuana Concentrates, 2020.

• Centers for Disease Control and Prevention. Understanding Your Risk for Cannabis Use Disorder, reviewed December 5, 2024.

• Centers for Disease Control and Prevention. Cannabis Frequently Asked Questions, reviewed January 31, 2025.

• Centers for Disease Control and Prevention. About Cannabis, reviewed February 15, 2024.

• Centers for Disease Control and Prevention. Cannabis and Mental Health, reviewed February 15, 2024.

• Centers for Disease Control and Prevention. Cannabis and Teens, reviewed February 15, 2024.

• Centers for Disease Control and Prevention. Cannabis and Driving, reviewed February 22, 2024.

• Vivolo-Kantor AM, Liu S, Tanz LJ, Mattson CL, Schier J. Trends in Emergency Department Visits Involving Cannabis Hyperemesis Syndrome Identified Using a New Diagnosis Code, United States, January 2023 to May 2026. MMWR Morbidity and Mortality Weekly Report, August 6, 2026.

• Office of the Surgeon General, U.S. Department of Health and Human Services. U.S. Surgeon General's Advisory: Marijuana Use and the Developing Brain, August 29, 2019.

• National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: Chapter 12, Mental Health. 2017, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. Highlights for the 2025 National Survey on Drug Use and Health, July 2026.

• Substance Abuse and Mental Health Services Administration. 2025 NSDUH Annual National Report, figure slides (Past Year Marijuana Use Disorder, 2021-2025), July 2026.

• Substance Abuse and Mental Health Services Administration. Table 2.2, DSM-IV to DSM-5 Withdrawal Symptom Comparison, in Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health. 2016, NCBI Bookshelf.

• StatPearls. Cannabis Use Disorder. NCBI Bookshelf, updated March 21, 2026.

• U.S. Food and Drug Administration. Marinol (dronabinol) capsules, prescribing information, revised March 2026.

• Substance Abuse and Mental Health Services Administration. Using SAMHSA Funds to Implement Evidence-Based Contingency Management Services. Advisory PEP24-06-001, 2025.

• Substance Abuse and Mental Health Services Administration. TAP 32: Clinical Drug Testing in Primary Care. SMA12-4668, 2012.

• U.S. Department of Health and Human Services. Mandatory Guidelines for Federal Workplace Drug Testing Programs: Oral Fluid. Federal Register, October 25, 2019, effective January 1, 2020.

• U.S. Department of Transportation, Office of Drug and Alcohol Policy and Compliance. DOT "CBD" Notice, February 18, 2020.

• U.S. Food and Drug Administration. 5 Things to Know about Delta-8 Tetrahydrocannabinol (Delta-8 THC), May 4, 2022.

• U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Drug Safety Communication, September 23, 2020.